(NASDAQ: LXRX) Lexicon Pharmaceuticals's forecast annual revenue growth rate of -24.48% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 79.5%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.92%.
Lexicon Pharmaceuticals's revenue in 2025 is $58,432,000.On average, 4 Wall Street analysts forecast LXRX's revenue for 2025 to be $15,038,171,625, with the lowest LXRX revenue forecast at $10,949,207,652, and the highest LXRX revenue forecast at $18,569,681,746. On average, 4 Wall Street analysts forecast LXRX's revenue for 2026 to be $5,135,552,690, with the lowest LXRX revenue forecast at $2,725,491,450, and the highest LXRX revenue forecast at $9,993,468,650.
In 2027, LXRX is forecast to generate $12,857,051,667 in revenue, with the lowest revenue forecast at $3,234,249,854 and the highest revenue forecast at $24,674,782,594.